Takeda Q1 Revenue +10.2% on Weak Yen; Pipeline Milestones on Track, FY Outlook Unchanged
TAK sits 34% above its 52-week low of $12.99.
Summary
Takeda reported Q1 FY2026 revenue of JPY 1,219.9B, up 10.2% on a weak yen but down 0.5% at constant currency, as VYVANSE generics continued to weigh. Core operating profit rose 11.5% on an AER basis, but core EPS fell 11.8% at CER. The company reaffirmed its full-year forecast, signaling no surprises. Pipeline progress includes the first approval for ORZEYFULTM in China, with launch preparations for rusfertide and zasocitinib on schedule. This follows the May 2026 FY2025 results and the recent CEO transition to Julie Kim, whose transformation plan is now in execution. A Capital Markets Day on December 11, 2026, will provide a detailed strategic roadmap. The results are broadly in line with expectations, but the constant-currency decline and sharp drop in adjusted free cash flow (down 63.9% YoY) warrant attention.
At the time of this announcement, TAK was trading at $17.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $55.9B. The 52-week trading range was $12.99 to $18.90. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.